Ann: Phase I Clinical Trial Data Review Complete, page-27

Agree plasma concentrations and half life are a concern to me
from a plasma ie blood, point of view, concentrations not that high and this is important from a blood sepsis perspective (ESKAPE organisms)
Appears to have a short plasma half life given how quickly it appears in the urine. Is this going to be a q4/24 or q6/24 dosing regime drug. There are other drugs that have this sort of IV dosing regime but this is not an attractive feature, But if it kills everything in sight and quickly probably not such a big issue.
encouraging news for sure, but UTI infections have a different revenue profile than Sepsis.
More cases of UTI's but probably can't charge anywhere near as much as you can for Sepsis
As i said, good news for sure (particularly in context of kidney function effects which are a significant consideration in elderly and septic patients) but a bit more work to do yet to see if it is a block buster like we all hope for
fingers crossed